Related Experiment Video

Updated: Aug 21, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Reassessing guidelines for heart failure

Helmut Drexler1, Kai C Wollert

  • 1Chief Cardiovascular Division, Medical University of Hanover, 30625, Germany. drexler.helmut@mh-hannover.de

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|November 5, 2004
PubMed

Insights

Recent heart failure management advances include ACE inhibitors as first-line treatment. New trials on angiotensin receptor blockers, beta-blockers, and aldosterone blockers are updating clinical guidelines.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Heart failure management has seen significant advancements.
  • Risk factor treatment, like for coronary artery disease, can prevent heart failure.
  • Established treatments and emerging therapies are shaping current practice.

Purpose of the Study:

  • To review recent clinical trial results in heart failure management.
  • To discuss the role of various drug classes in treating heart failure.
  • To inform the update of heart failure clinical guidelines.

Main Methods:

  • Review of key clinical trials including those for ACE inhibitors, ARBs, beta-blockers, and aldosterone receptor blockers.
  • Discussion of trial outcomes regarding survival and symptomatic benefits.
  • Analysis of specific drug data, including candesartan in preserved ejection fraction heart failure and carvedilol vs. metoprolol tartrate.

Main Results:

  • Angiotensin-converting enzyme (ACE) inhibitors demonstrate long-term survival and symptomatic benefits, confirming their first-line status.
  • Angiotensin receptor blockers (ARBs) show efficacy, with emerging data for candesartan in specific heart failure types.
  • The COMET trial suggests potential clinical differences among beta-blockers; eplerenone shows promise in post-MI heart failure patients.

Conclusions:

  • Current evidence supports ACE inhibitors as foundational therapy for heart failure.
  • ARBs, beta-blockers, and aldosterone receptor blockers represent important therapeutic options with evolving roles.
  • These clinical trial findings are actively influencing the revision of heart failure management guidelines.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...